Incyte Stock On Fire: Up 17% With 5-Day Winning Streak
Incyte (INCY) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 17% return. The company has gained about $3.0 Bil in value over the last 5 days, with its current market capitalization at about $21 Bil. The stock remains 53.0% above its value at the end of 2024. This compares with year-to-date returns of 15.6% for the S&P 500.
INCY provides discovery, development, and commercialization of proprietary therapeutics, including clinical-stage drugs targeting chronic graft-versus-host disease and various cancers. After this rally, is INCY still a buy – or is it time to lock in gains? Deep dive with Buy or Sell INCY.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. Separately, consider what the long-term performance for your portfolio could be if you combined 10% commodities, 10% gold, and 2% crypto with equities.
Comparing INCY Stock Returns With The S&P 500
The following table summarizes the return for INCY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | INCY | S&P 500 |
|---|---|---|
| 1D | 2.7% | 0.4% |
| 5D (Current Streak) | 17.2% | -1.4% |
| 1M (21D) | 21.3% | 1.2% |
| 3M (63D) | 35.2% | 7.2% |
| YTD 2025 | 53.0% | 15.6% |
| 2024 | 10.0% | 23.3% |
| 2023 | -21.8% | 24.2% |
| 2022 | 9.4% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has INCY behaved after prior drops? See INCY Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 41 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 44 |
| 4D | 3 | 8 |
| 5D | 11 | 2 |
| 6D | 0 | 3 |
| 7D or more | 0 | 5 |
| Total >=3 D | 41 | 62 |
Key Financials for Incyte (INCY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.7 Bil | $4.2 Bil |
| Operating Income | $649.7 Mil | $101.3 Mil |
| Net Income | $597.6 Mil | $32.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.2 Bil | $1.4 Bil |
| Operating Income | $310.8 Mil | $431.3 Mil |
| Net Income | $405.0 Mil | $424.2 Mil |
While INCY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.